Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.41 |
| ▸ | SLC2A3 | P11169 | 4/20 | 0.41 |
| ▸ | SLC2A2 | P11168 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071445 | 0.84 | GSK3B (0.55) | GSK3BALDH1A1MAP4K1SLC2A1SLC2A3 | |
| SCHEMBL6071515 | 0.81 | GSK3B (0.63) | GSK3BALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL839950 | 0.76 | SLC2A1 (0.60) | GSK3BALDH1A1SLC2A1SLC2A3SLC2A2 | |
| SCHEMBL840321 | 0.76 | GSK3B (0.52) | GSK3BALDH1A1SLC2A1SLC2A3SLC2A2 | |
| SCHEMBL838951 | 0.75 | SLC2A1 (0.65) | GSK3BSLC2A1SLC2A3SLC2A2MAPT | |
| SCHEMBL8345510 | 0.74 | GSK3B (0.75) | GSK3B | |
| SCHEMBL6071677 | 0.74 | GSK3B (0.75) | GSK3B | |
| SCHEMBL2499455 | 0.74 | XDH (0.71) | ALDH1A1SLC2A1SLC2A3SLC2A2MAPT | |
| SCHEMBL8342930 | 0.73 | GSK3B (0.79) | GSK3B | |
| SCHEMBL839952 | 0.73 | MAPK14 (0.47) | ALDH1A1MAPTNPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167020-A1 | Pyrazolopyrimidines as kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2004009597-A2 | PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167020-A1 | Pyrazolopyrimidines as kinase inhibitors | MAP3K12, MAP3K5, MAP3K2 | GSK3B 591/4885ALDH1A1 2729/4885MAP4K1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.